Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Uveal Melanoma 2Conjunctival Neoplasms 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Ranibizumab × Clear all
NCT00680225 2017-04-12

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

New England Retina Associates

Phase 3 Completed
10 enrolled 4 charts
Dermatologic

Uveal Melanoma

NCT01251978 2016-10-19

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New England Retina Associates

Phase 2 Completed
10 enrolled 7 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡